Analysts Set IQVIA Holdings Inc. (NYSE:IQV) Target Price at $251.22

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average rating of “Moderate Buy” from the twenty-one brokerages that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $251.22.

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Truist Financial reissued a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. UBS Group cut their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Stifel Nicolaus reduced their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Robert W. Baird reduced their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Private Trust Co. NA boosted its holdings in IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares during the period. Clear Harbor Asset Management LLC lifted its position in IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after purchasing an additional 50 shares during the last quarter. Pine Valley Investments Ltd Liability Co boosted its stake in shares of IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 50 shares during the period. Howard Capital Management Inc. grew its holdings in shares of IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after purchasing an additional 54 shares during the last quarter. Finally, Fortitude Family Office LLC increased its stake in shares of IQVIA by 2.9% in the third quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after buying an additional 56 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 1.9 %

IQVIA stock opened at $194.71 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a fifty day simple moving average of $199.52 and a 200 day simple moving average of $215.96. The company has a market cap of $34.29 billion, a P/E ratio of 25.96, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.